Peter Rankin

Vice President
Peter Rankin Life Sciences Litigation Charles River Associates

Dr. Peter J. Rankin is a Vice President in CRA’s Life Sciences Practice.  He advises clients on competition, commercial disputes, intellectual property, and policy issues across a broad range of companies within the life sciences industry.  He has more than two decades of experience in conducting economic analyses to address issues in the US, UK, Europe, Latin America, and global jurisdictions.

Dr. Rankin’s litigation support assistance for industry leading clients has included evaluating breakdowns in development and commercialization agreements, including assessment of efforts clauses; assessing antitrust claims related to patent settlements, lifecycle management strategies, and incremental innovations; calculating damages; assessing commercial success; evaluating the effect of label claims on competition and consumer uptake; evaluating harm from appropriation of early-stage and pre-clinical intellectual property; and evaluating potential competitive or cost implications of proposed legislative proposals.

Dr. Rankin has assisted clients with products in a variety of therapeutic categories or diagnostic categories, with a particular focus in oncology, anti-infectives, blood factor, cardiovascular, and central nervous system therapies.  In medical devices, he has evaluated existing and developmental diagnostic products, several types of surgical implants, monitoring devices, and companion diagnostics used with therapeutic options.  Dr. Rankin has also evaluated medical software products including second-opinion, reimbursement, and physician management system software.

Dr. Rankin has given oral and written expert testimony in US litigation cases involving competition, intellectual property, and commercial disputes.  He has also provided written and oral testimony in arbitration cases and has testified before the Antitrust Task Force of the US House of Representatives Committee of the Judiciary.

Dr. Rankin has authored public and proprietary policy evaluation projects involving healthcare reform, reimbursement methodologies, antitrust exemptions, research and development incentives, and research productivity. While a doctoral candidate at Duke University, Dr. Rankin was a researcher at the Center for Health Policy, Law, and Management, where he published papers on hospital conversions, medical malpractice insurance and managed care quality, satisfaction, and participation. His dissertation research, completed in 1999, evaluated pricing and product differentiation in the Medicare-managed care market.

Selected Engagements

  • 01
    AAA dispute involving the breach of a contract between biopharmaceutical companies engaged in the development of monoclonal antibody therapeutics
    In an American Arbitration Association (AAA) dispute over early-stage drug candidates in a development agreement between two biopharmaceutical companies, CRA...
    View engagement
  • 02
    At risk generic entry and impact of formulary status
    In a Hatch-Waxman litigation, a first-to-file generic manufacturer asked CRA to assess changes in formulary status that would result from the at-risk entry and...
    View engagement
  • 03
    Evaluation of alleged manipulation of industry drug standard setting
    In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and...
    View engagement